摘要
目的初步探讨塞来昔布联合多柔比星(ADM)对人乳腺癌细胞MCF-7的增殖和凋亡的影响,及其可能机制。方法用不同浓度的塞来昔布溶液、ADM溶液及二者联合用药(简称3药)分别与MCF-7细胞共育24h、48h、72h后,MTT法测定其对细胞的抑制作用。分别用3药作用MCF-7细胞48h后,流式细胞仪检测细胞周期和凋亡。结果10mg/L多柔比星、50μmol/L塞来昔布溶液分别与MCF-7细胞共育24h后,对MCF一7细胞的生长均有明显抑制作用(P〈0.01)。联合用药组的抑制作用更为显著。流式细胞术检测发现,给药细胞48h后,G0/G1期细胞比例升高,S期和G2/M期比例下降,3个给药组细胞均形成明显的凋亡峰,实验组各组与对照组的凋亡率差异有统计学意义(P〈0.01)。结论①塞来昔布和多柔比星均有抑制乳腺癌MCF-7细胞的作用,并呈时间和剂量依赖性;②塞来昔布能诱导MCF-7细胞凋亡,可能与阻止细胞周期进展有关;③塞来昔布与多柔比星联合应用可起到协同抗肿瘤的作用。
Objective To study the roles of celecoxib and adriamycin in the inhibition of proliferation and the induction of apoptosis human breast cancer cells MCF-7. Methods MCF-7 cells together with celecoxib or/and adriamycin of different concentration after fostering 24,48,72 hours were carried out, the inhibition of pro- liferation was measured by MTF assay. Cell cycle and apoptotic percentage were analyzed by flow cytometry (FCM). Results MCF-7 cells together with adriamycin (10mg/L) after fostering 24 hours were pressed down obviously(P 〈 0.01 ) , MCF-7 cells together with celecoxib (50μmol/L) after fostering 24 hours were pressed down obviously( P 〈 0.01 ) , the effect was more obviously in the group of celecoxib combined and ADM. The flow cytometry shows that the proportion of G0/G1 phase and the apoptotic rate wee incresed significantly in all groups, the apoptotic rate was significant between all groups and control group(P 〈 0.01 ). Conclusions The inhibition of celecoxib and adriamycin against human breast cancer MCF-7 is obviously with time dependence and dose dependence. Celecoxib can induce the apoptosis of human breast cancer MCF-7. Anti-tumor action of celecoxib combined and adriamycin against human breast cancer is cooperated.
出处
《中华内分泌外科杂志》
CAS
2010年第1期13-16,共4页
Chinese Journal of Endocrine Surgery
基金
江苏省连云港市2009年医学重点人才医药卫生科研课题(ZC317)